title: De novo membrano-proliferative nephritis following interferon therapy for chronic hepatitis C (case study and literature review).
authors: Division of Nephrology, Maggiore Hospital, IRCCS Foundation, Pad. Croff, Via Commenda 15, 20122, Milan, Italy, fabrizi@policlinico.mi.it.
authors: Fabrizio
authors: F
authors: Fabrizi
authors: Alessio
authors: A
authors: Aghemo
authors: Gabriella
authors: G
authors: Moroni
authors: Patrizia
authors: P
authors: Passerini
authors: Roberta
authors: R
authors: D'Ambrosio
authors: Paul
authors: P
authors: Martin
authors: Piergiorgio
authors: P
authors: Messa
mesh_terms: D000998:Antiviral Agents / Q000009:adverse effects* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D015432:Glomerulonephritis, Membranoproliferative / Q000139:chemically induced* / Q000175:diagnosis; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000009:adverse effects* / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use; D012254:Ribavirin / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b